4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 性质
| 沸点 | 749.2±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.474±0.06 g/cm3(Predicted) |
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | DMSO:15.0(最大浓度 mg/mL);23.9(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 3.15±0.10(Predicted) |
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 用途与合成方法
|
STAT3 6.8 μM (IC 50 ) |
BP-1-102 binds Stat3 with an affinity K D of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro , with an IC 50 value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8.
Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth.
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-100493 | 4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 | 1334493-07-0 | 5mg | 950 |
| 2024-01-25 | HY-100493 | 4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 | 1334493-07-0 | 10mM * 1mLin DMSO | 1310 |
